Cerus Corporation
$ 2.38
0.00%
24 Feb - close price
- Market Cap 457,168,000 USD
- Current Price $ 2.38
- High / Low $ 2.48 / 2.37
- Stock P/E N/A
- Book Value 0.32
- EPS -0.08
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.28 %
- 52 Week High 2.96
- 52 Week Low 1.12
About
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Analyst Target Price
$4.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-07-30 | 2025-04-30 | 2025-03-03 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 | 2023-08-02 | 2023-05-04 |
| Reported EPS | 0 | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 | -0.06 | -0.09 |
| Estimated EPS | -0.0075 | -0.03 | -0.0225 | -0.05 | -0.01 | -0.03 | -0.04 | -0.05 | -0.02 | -0.05 | -0.06 | -0.07 |
| Surprise | 0.0075 | 0.0299 | -0.0075 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0.01 | 0.02 | 0 | -0.02 |
| Surprise Percentage | 100% | 99.6667% | -33.3333% | 20% | 0% | 33.3333% | 25% | 0% | 50% | 40% | 0% | -28.5714% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2026-02-20 14:03:50
Cerus Corporation (Nasdaq: CERS) announced that its management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be available on the company's investor relations page, with a replay accessible for 90 days. Cerus is dedicated to blood supply safety, developing pathogen-protected blood components globally.
2026-02-18 06:27:33
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after market close. The company will also host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview. Interested parties can access the webcast and presentation slides via the Investor Relations page of the Cerus website.
2026-02-17 21:27:57
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview and outlook. A replay of the webcast will be available on the Cerus website until March 23, 2026.
2026-01-23 22:04:35
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the 2026 annual meeting of stockholders, with his current term expiring at that meeting. His decision was not due to any disagreements with the company. This announcement follows recent positive financial news for Cerus, including strong preliminary fourth-quarter product revenue and a new purchasing agreement.
2026-01-23 17:45:45
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the company's 2026 annual meeting, with his decision not stemming from any disagreements regarding the company's operations. The company's stock, CERS, currently holds a "Hold" rating with a $2.50 price target from analysts, while TipRanks' AI Analyst, Spark, assesses CERS as "Neutral" due to weak financial fundamentals despite a strong uptrend in technicals. The article also highlights ongoing losses, high leverage, deteriorating free cash flow, and overbought signals as contributing factors to its neutral outlook.
2026-01-22 18:27:27
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the company's 2026 annual meeting, with his departure not stemming from any disagreements. TipRanks' AI Analyst, Spark, rates CERS stock as Neutral due to weak financial fundamentals despite a positive earnings outlook and strong technicals. The stock has a Hold rating from analysts with a $2.50 price target.
